Lasker, Keren
Boeynaems, Steven
Lam, Vinson
Scholl, Daniel
Stainton, Emma http://orcid.org/0000-0002-4247-8059
Briner, Adam http://orcid.org/0000-0002-4760-5037
Jacquemyn, Maarten http://orcid.org/0000-0003-2626-4189
Daelemans, Dirk http://orcid.org/0000-0001-7092-1153
Deniz, Ashok
Villa, Elizabeth http://orcid.org/0000-0003-4677-9809
Holehouse, Alex S. http://orcid.org/0000-0002-4155-5729
Gitler, Aaron D. http://orcid.org/0000-0001-8603-1526
Shapiro, Lucy http://orcid.org/0000-0002-0445-067X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35-GM118071)
L.S. is a BioHub investigator
Article History
Received: 6 June 2022
Accepted: 9 September 2022
First Online: 26 September 2022
Competing interests
: A.S.H. is a scientific consultant with Dewpoint Therapeutics. A.D.G. has served as a consultant for Aquinnah Pharmaceuticals, Prevail Therapeutics and Third Rock Ventures and is a scientific founder of Maze Therapeutics. L.S. is on the Board of Directors of Pacific Biosciences, Inc and 5Metis, Inc. Chan Zuckerberg Biohub, Inc. and The Board Of Trustees Of The Leland Stanford Junior University filed a patent application that describes the PopTag technology, parts of which are introduced and described in this work, on behalf of inventors K.L., S.B, A.D.G, and L.S. (PCT/ WO2021113598A3). V.L, D.S., E.S., A.B., M.J., D.D., A.D., and E.V. declare no competing interests.